Cell-Based Assay Services for Alzheimer’s Disease R&D
At Ace Therapeutics, we empower researchers and drug developers with cutting-edge cell-based assays tailored to unravel the complexities of Alzheimer's disease. Our preclinical services leverage human-relevant models and advanced technologies to evaluate drug efficacy, neurotoxicity, and disease mechanisms—helping you prioritize candidates with the highest therapeutic potential.
Alzheimer's drug discovery demands models that recapitulate the disease's hallmark pathologies—amyloid-beta aggregation, tau hyperphosphorylation, and neuroinflammation. Traditional animal models often fail to predict human-specific responses, leading to costly late-stage failures. Our cell-based platforms bridge this gap by
We engineer physiologically accurate systems to study AD pathology.
Quantify therapeutic effects on AD-specific pathways.
Identify hits while minimizing off-target risks.
Tailored solutions for unique therapeutic modalities.
At Ace Therapeutics, we combine innovative tools with deep neurobiological expertise to address Alzheimer's multifaceted pathology. Our technologies are engineered to replicate disease mechanisms with precision, from amyloid-beta aggregation and tau propagation to neuroinflammatory cascades. Below are the platforms driving our assays—scalable, human-relevant, and designed to deliver actionable insights at every stage of preclinical development.
| Technology | Application |
| AI-driven phenotype analysis | Automates neurite outgrowth and plaque quantification in high-throughput screens. |
| Single-cell RNA sequencing | Identifies AD-specific biomarker signatures in heterogeneous cultures. |
| Microfluidic 3D spheroids | Models Aβ plaque deposition and tau spreading in a tissue-like environment. |
| High-content imaging (HCI) | Tracks autophagy flux and lysosomal dysfunction in real time. |
In the race to combat Alzheimer's, cell-based assays are your first line of defense against translational failures. Ace Therapeutics combines cutting-edge models, scalable platforms, and deep disease expertise to illuminate the path from bench to preclinical success. Contact us today to build a tailored testing strategy that aligns with your scientific goals.
What cell types do you offer for neuroinflammation studies
We provide co-culture systems with iPSC-derived neurons, microglia, and astrocytes to model cytokine cross-talk and synaptic loss.
Can you support gene therapy validation
Yes. Our CRISPR-edited models and MEA platforms are ideal for testing AAV or CRISPR-based therapies targeting tau or APOE.
How much compound is required for screening
Most HTS assays require 1–5 mg for small molecules or 0.2–1 mg for biologics. Microscale assays reduce material needs by 50%.
Do you provide data on amyloid-beta oligomers vs fibrils
Absolutely. Our FRET-based assays distinguish oligomer formation, while Congo red staining quantifies fibrillar aggregates.
What turnaround times can I expect
High-throughput screens take 2–3 weeks. Custom 3D spheroid or organ-on-chip studies require 6–8 weeks.
Our products and services are for research use only and can not be used for diagnostic or other purposes.
Make Order
Experimental Scheme
Implementation
Conclusion
Ace Therapeutics is a specialized team of scientists and technical professionals committed to working closely with clients worldwide. We offer comprehensive preclinical testing solutions to support the development of novel therapies and medications across a range of disease areas.
Ace Therapeutics boasts a team of highly committed and skilled researchers dedicated to delivering innovative preclinical contract research solutions.
We provide tailored preclinical services designed to streamline your research process and advance promising concepts into actionable insights, ensuring efficient progress in drug development.